Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Recruiting · NCT07623668 · Interventional (participants receive a specific treatment) · Lead sponsor: Oculis
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Who can take part
Age range
18 Years to 50 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.
- Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.
- Key
Exclusion criteria
- \- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety
Where it is running
4 locations listed across 3 US states.
- Kahana Oculoplastic and Orbital Surgery - Livonia, Michigan, United States
- Medical University of South Carolina, Storm Eye Institute - Charleston, South Carolina, United States
- UT Southwestern Medical Center (Ophthalmology CRU) - Dallas, Texas, United States
- Neuro-Eye Clinical Trials - Houston, Texas, United States